David Guyer

Venture Partner

David has significant medical, drug development and commercial experience in ophthalmology. He joined SV Health Investors as a Venture Partner in 2006

He serves as the Chief Executive Officer and Chairman of the Board of Ophthotech. Under David’s leadership, Ophthotech raised more than $350 million in financing in the five-month period from May to September 2013, including a $192 million initial public offering, a multi-tranched $125 million royalty financing deal with Novo A/S and a $50 million Series C private funding round. In the first quarter of 2014, Ophthotech also successfully completed a follow-on public offering resulting in gross proceeds to the Company of $59.9 million and closed the second tranche of our royalty financing. In May of 2014, Ophthotech entered into an ex-US licensing and commercialization deal for Fovista®, a novel anti-PDGF agent in Phase 3 trials for wet age-related macular degeneration, with Novartis potentially worth over $1 billion, inclusive of $330 million in an upfront fee ($200 million) and near-term enrollment milestones ($130 million), excluding future royalties, which places the deal as one of the largest ex-US partnering transactions ever in the biotechnology industry.

Prior experience
Following a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine, David co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings over $400 million, including a $157 million IPO offering. He also oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for wet AMD, on which Eyetech partnered with Pfizer in a deal valued at over $750 million, excluding royalties. Under his leadership, Eyetech reached a peak market capitalization of approximately $2 billion. At the time, the Macugen launch was in the top 10 percent of pharmaceutical first-year launches. OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued at $935 million. Prior to joining Ophthotech, David previously worked as a venture capitalist and Partner at SV, and has served on multiple boards of both public and private companies.

Academic credentials
BS, Yale College, summa cum laude; MD, Johns Hopkins University School of Medicine; ophthalmology residency, Wilmer Ophthalmological Institute at Johns Hopkins Hospital; retinal fellowship, Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Outside of SV
David serves on the Boards of AGTC and Thrombogenics

Venture Partners


Sector Administrator
Mala Hintzen


Current Portfolio

Past Portfolio

Imagen Biotech, Inc.
Link Medicine, LLC
Lux Biosciences, Inc.
NeoVista, Inc.
Neurotech Pharmaceuticals, Inc.
Ophthotech Corporation